| pubmed-article:9740071 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9740071 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9740071 | lifeskim:mentions | umls-concept:C0009402 | lld:lifeskim |
| pubmed-article:9740071 | lifeskim:mentions | umls-concept:C0085533 | lld:lifeskim |
| pubmed-article:9740071 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:9740071 | lifeskim:mentions | umls-concept:C0812425 | lld:lifeskim |
| pubmed-article:9740071 | lifeskim:mentions | umls-concept:C0242793 | lld:lifeskim |
| pubmed-article:9740071 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9740071 | pubmed:dateCreated | 1998-9-21 | lld:pubmed |
| pubmed-article:9740071 | pubmed:abstractText | Adjuvant chemotherapy for colorectal carcinoma was found to improve survival of patients with American Joint Committee on Cancer/International Union Against Cancer Stage III disease. The usefulness of chemotherapy in patients with Stage II disease continues to be debated, and it is likely that only those patients with a poor prognosis should receive adjuvant chemotherapy. Biologic prognostic factors may allow further insight into the optimal treatment strategy for patients with Stage II or earlier disease. In this study the prognostic role of S-phase fraction (SPF) determined by flow cytometry was assessed in patients with Stage I-II colorectal carcinoma. | lld:pubmed |
| pubmed-article:9740071 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9740071 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9740071 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9740071 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9740071 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9740071 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:ValentiniMM | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:CatalanoGG | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:GrazianoFF | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:CascinuSS | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:BartolucciMM | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:GriantiCC | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:Del FerroEE | lld:pubmed |
| pubmed-article:9740071 | pubmed:author | pubmed-author:LigiMM | lld:pubmed |
| pubmed-article:9740071 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9740071 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:9740071 | pubmed:volume | 83 | lld:pubmed |
| pubmed-article:9740071 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9740071 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9740071 | pubmed:pagination | 1081-5 | lld:pubmed |
| pubmed-article:9740071 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:meshHeading | pubmed-meshheading:9740071-... | lld:pubmed |
| pubmed-article:9740071 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9740071 | pubmed:articleTitle | S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma: implications for adjuvant chemotherapy. | lld:pubmed |
| pubmed-article:9740071 | pubmed:affiliation | Sezione di Oncologia Sperimentale, Unità Operativa di Oncologia Medica, Pesaro, Italy. | lld:pubmed |
| pubmed-article:9740071 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9740071 | lld:pubmed |
